The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 346:536-538 February 14, 2002 Number 7
NextNext

Polymorphisms of the ß2-Adrenergic Receptor

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
To the Editor: Dishy et al. (Oct. 4 issue)1 report that polymorphisms of the {beta}2-adrenergic receptor influence agonist-promoted desensitization of {beta}2-adrenergic receptor–mediated vasodilatation. Desensitization can be an important homeostatic event but may also limit the therapeutic effectiveness of agonists (a response called tachyphylaxis). The authors indicate that their findings were unexpected, given results of in vitro studies in which my colleagues and I used polymorphic {beta}2-adrenergic receptors that were expressed in cells in either recombinant2 or native3 form. However, the effect of polymorphisms in vivo is dependent on whether receptors are under static or dynamic regulation. The concept (Figure . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.